Earlier is better for HPV vaccines. A cluster randomized trial found that kids who started the HPV vaccine series at ages 9–10 were more than twice as likely to complete both doses compared to those who started at 11–12. Researchers are now calling on policymakers to make earlier vaccination a preferential recommendation, not just a permitted option.
Earlier is better for HPV vaccines
A large cluster randomized trial across 31 U.S. pediatric practices found that recommending HPV vaccination starting at ages 9–10 significantly boosted both initiation and completion rates compared to the standard start at ages 11–12. The study, presented at IDWeek 2026, included over 62,000 children and adolescents — and the results were striking.
Importantly, the earlier start didn't crowd out other vaccines or reduce well-child visit rates, addressing a key concern going in. Researchers also noted that the 9-year-old wellness visit is less vaccine-heavy, giving clinicians a better opportunity to frame HPV vaccination as cancer prevention rather than a conversation tied to sexual health.
By the Numbers
Why it matters: HPV vaccination is highly effective at preventing HPV-related cancers, but uptake hasn't reached herd immunity levels. Shifting the recommended start age to 9–10 — rather than merely permitting it — could meaningfully close that gap and protect more kids before exposure risk rises.
